drugset / Trial / NCT02517866

Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia

NCT02517866

Phase 4 Completed 380 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil (AZM) in Asian adult participants with both essential hypertension and type 2 diabetes.

Timeline

Start
2015-07-13
Primary completion
2016-11-15
Completion
2016-11-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan medoxomil Other / unclassified 40 mg Oral
Subject Azilsartan medoxomil Other / unclassified 80 mg Oral